Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1613 1632
This examiner grants 62% of resolved cases
Briana Noel Ebbinghaus is an examiner in Tech Center 1600 and Art Unit 1613. She has 72 resolved cases with an allowance rate of 62.5 percent. The median days to allowance for these cases is 1435. This 1435-day duration is a key factor for applicants to consider when prosecuting the 72 resolved cases in this unit.
The interview lift is 62.7 percent, which is exceptionally high. This 62.7 percent lift suggests that interviews are almost essential for success, nearly doubling the effective success rate compared to the 62.5 percent baseline. Practitioners should prioritize direct engagement to navigate the 1435 median days to allowance in Art Unit 1613. The 72 resolved cases in Tech Center 1600 demonstrate that the 62.7 percent lift is a primary driver of favorable outcomes.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17054791 | RAAV VECTORS ENCODING OF LYSOSOMAL BETA-GALACTOSIDASE (GLB1) AND CATHEPSIN A | Final Rejection | University of Massachusetts |
| 17794166 | TRANSPOSON SYSTEMS FOR GENOME EDITING | Final Rejection | The Regents of the University of California |
| 17286276 | COMPOSITIONS AND METHODS FOR DELIVERING TRANSGENES | Final Rejection | BAYER HEALTHCARE LLC |
| 17920599 | STEM CELL DERIVED SINGLE-ROSETTE BRAIN ORGANOIDS AND RELATED USES THEROF | Non-Final OA | The Regents of the University of Michigan |
| 18007677 | CORONAVIRUS VACCINE CONSTRUCTS AND METHODS OF MAKING AND USING SAME | Non-Final OA | Washington University |
| 17429452 | GENETICALLY MODIFIED GAMMA DELTA T CELLS AND METHODS OF MAKING AND USING | Non-Final OA | Regents of the University of Minnesota |
| 19259714 | HUMAN SPINAL CORD INJURY ORGANOIDS | Non-Final OA | Northwestern University |
| 18735858 | HUMAN SPINAL CORD INJURY ORGANOIDS | Non-Final OA | Northwestern University |
| 18772579 | SCALABLE BIOMANUFACTURING OF TUMOR ORGANOIDS | Non-Final OA | The Board of Trustees of The University of Alabama |
| 18000414 | LARGE-SCALE PRODUCTION OF EXOSOMES FROM PRIMED MESENCHYMAL STROMAL CELLS FOR CLINICAL USE | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17755881 | NATURAL KILLER CELL IMMUNOTHERAPY FOR THE TREATMENT OF GLIOBLASTOMA AND OTHER CANCERS | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17603329 | CRISPR/CAS-BASED GENOME EDITING COMPOSITION FOR RESTORING DYSTROPHIN FUNCTION | Final Rejection | Duke University |
| 17911953 | USE OF EPHB4 AS A TARGET IN SCREENING DRUGS OR MODELS FOR INCREASING INSULIN SENSITIVITY | Final Rejection | Institute of Materia Medica, Chinese Academy of Medical Sciences |
| 18031771 | HEPATOCYTE-LIKE CELLS | Final Rejection | Sana Biotechnology, Inc. |
| 18010667 | SOMATIC STEM CELL-ACCUMULATED TISSUE CONSTRUCT AND DEVICE FOR PRODUCING THE SAME | Final Rejection | BIOTUBE CO., LTD. |
| 17595220 | ONCOLYTIC VIRUS WITH IMPROVED SAFETY AND ANTICANCER EFFECTS | Non-Final OA | BIONOXX INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy